⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

March 17, 2026ESMO OpenOpen Access

26P Capmatinib combined with EGFR-TKI in EGFR-mutant non-small cell lung cancer with MET overexpression and acquired resistance to prior EGFR inhibitors

Z. Han X. Qin J. Tang H. Wang Y. Zhao W. Liu H. Liu Y. Ge

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate the effectiveness and safety of capmatinib combined with EGFR-TKI in EGFR-mutant non-small cell lung cancer patients.
Participants received an oral combination of aumolertinib and etoposide.
Adverse events were monitored and compared with established safety profiles.
Clinical trial identified as NCT06463171.
Notable adverse events included anemia (18.3%), urinary tract infection (11.7%), and decreased neutrophil count (10.0%).
No new safety signals were detected compared to individual drugs.
The combination demonstrated promising antitumor activity.

Implication

Clinical trial shows antitumor activity with manageable safety in EGFR-mutant non-small cell lung cancer, suggesting a promising treatment approach.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Han et al. (2026) studied this question.

synapsesocial.com/papers/69be35166e48c4981c673387 https://doi.org/10.1016/j.esmoop.2026.106333

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non–Small-Cell Lung CancerEarly-Phase Clinical Trial · 2021 · 34 citations
227P Chemotherapy (chemo) rechallenge in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC who discontinued 1L osimertinib (osi) + platinum–pemetrexed (plat–pem) due to progression (PD): FLAURA2 exploratory analysisClinical Trial · 2026
3A randomized phase II study of capmatinib plus osimertinib with or without ramucirumab in patients with <i>EGFR</i> -mutant, <i>MET</i> -amplified stage IV or recurrent no–small cell lung cancer (Lung-MAP Sub-Study S1900G).Human Clinical Trial · 2026
4Complete Metabolic Remission With Dose Frequency-Modified Tepotinib Following Capmatinib Intolerance in MET Exon 14-Mutated Non-small Cell Lung Cancer (NSCLC): A Case ReportCase Report · 2026
5First-line Aumolertinib (EGFR tyrosine kinase inhibitor) plus apatinib (VEGFR inhibitor) versus aumolertinib in EGFR-mutant non-small cell lung cancer patients: a randomized, multicenter, phase II trialHuman Clinical Trial · 2026

More related papers

Amivantamab plus capmatinib in advanced non-small cell lung cancer (NSCLC) harboring <i>MET</i> alterations: Recommended phase 2 combination dose and preliminary dose-escalation results from the phase 1/2 METalmark study.2024
Efficacy and Safety of Aumolertinib/Icotinib Combination Therapy for Naive <i>EGFR</i> -Mutant NSCLC Patients with Brain Metastases: A Phase I/II Study2026
Efficacy and tolerability of capmatinib in a very elderly patient with metastatic NSCLC harboring a <i>MET</i> exon 14 mutation2024

More from ESMO Open

Comparison of intensity-modulated proton therapy (IMPT) and intensity-modulated radiotherapy (IMRT) for oropharyngeal cancer: efficacy and toxicity differ by outcome measureTue,
Adjuvant therapy for RCC: considerations beyond survival metricsTue,